/ Print /

MHE Articles

Expert Predictions: Generic Drug Costs, Biosimilar Impact, Policy ChangesHow are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
Five factors driving up the cost of oncology drugsThe high cost of specialty drugs continues to plague the healthcare industry. Here’s why.
Four reasons COPD patients don’t receive the right treatmentsMany providers are overlooking important steps that can help guide proper COPD treatment and therefore, reduce admissions and readmissions.
Six things to know about CMS' new bundled payment modelCMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know
Four things to know about your millennial workforceHow actively engaging millennials can help manage healthcare staffing challenges.
Despite hype, private payers slow to adopt oncology value-based modelsOncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.
Trump’s impact on ACA enrollment: What you need to knowHow did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.
Four COPD treatment changes to watchPending and recently approved treatment options for patients with chronic obstructive pulmonary disease range from biologics to a triple-drug inhaler.
How health execs can partner with pharmacists to address opioidsDirector of medication safety and quality for the American Society of Health-System Pharmacists shares how providers can better work with pharmacists to address the opioid epidemic.
Most employees unsatisfied with employers' well-being programsWillis Towers Watson research finds a dramatic increase among employers seeking to differentiate their health and well-being programs for competitive advantage.